[Therapy of lipoproteinemia. Comparison between Lipo-Merz retard and a commercial combination drug].
A total of 98 patients selected and classified into type IIa and IIb hyperlipoproteinemia according to Fredrickson and Lees (1965) were pre-treated for 6 months with a commercially available combination product (containing clofibrate and nicotinic acid). After randomization this pre-treatment was followed by a further 8 week-treatment with the comparison product (group I = 49 patients) or by a change-over to Lipo-Merz retard (group II = 49 patients). Lipo-Merz retard was administered in a dosage of one capsule/day, the combination product in a dosage of one capsule three times daily. In group I the serum cholesterol and serum triglyceride values achieved by the pre-treatment could be lowered by an average of 4%. In group II the reductions were 4% and 6%, respectively. Toleration was good in both groups.
D000328:Adult; D000368:Aged; D002784:Cholesterol / Q000097:blood; D002994:Clofibrate / Q000627:therapeutic use*; D002995:Clofibric Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D003692:Delayed-Action Preparations; D004338:Drug Combinations; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D006951:Hyperlipoproteinemias / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009525:Niacin; D009539:Nicotinic Acids / Q000627:therapeutic use*; D014280:Triglycerides / Q000097:blood
D003692:Delayed-Action Preparations; D004338:Drug Combinations; D009539:Nicotinic Acids; D014280:Triglycerides; C009746:etofibrate; D009525:Niacin; D002995:Clofibric Acid; D002784:Cholesterol; D002994:Clofibrate
Therapie der Hyperlipoproteinämie. Vergleich zwischen Lipo-Merz retard und einem handelsüblichen Kombinationspräparat.